Findings highlight the novel mechanism of action and potential for therapeutic activity in highly inflammatory autoimmune disease

研究结果突出了高度炎症性自身免疫性疾病的新作用机制和治疗活性潜力

SEATTLE, May 3, 2024 /PRNewswire/ -- Mozart Therapeutics, the leading developer of CD8 Treg network modulators, today announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells. The data will be presented during the Immunology 2024 meeting, May 3–7 in Chicago, Illinois. .

2024年5月3日，西雅图/PRNewswire/--CD8 Treg网络调节剂的主要开发人员Mozart Therapeutics今天宣布发布其第二个项目的新临床前数据，这是一种靶向CD8调节性T细胞的KIR x ICOS双特异性抗体。这些数据将在5月3日至7日于伊利诺伊州芝加哥举行的2024年免疫学会议上公布。。

Presentation highlights demonstrate KIR x ICOS Modulator:

演示亮点展示了KIR x ICOS调制器：

Restores and potentiates CD8 Treg function through binding the inhibitory receptor KIR and the costimulatory receptor ICOS, both expressed on CD8 Treg

通过结合CD8 Treg上表达的抑制性受体KIR和共刺激受体ICOS来恢复和增强CD8 Treg功能

Selectively activates CD8 Treg with dose-dependent increases in both their prevalence and capacity to eliminate pathogenic CD4 T cells

选择性激活CD8 Treg，其患病率和消除致病性CD4 T细胞的能力均呈剂量依赖性增加

Enhances ICOS signaling only in CD8 Treg and not other ICOS-expressing immune cells

仅在CD8 Treg中增强ICOS信号传导，而不增强其他表达ICOS的免疫细胞

Reduces proinflammatory cytokines and improves survival in a highly inflammatory disease model

在高度炎症性疾病模型中减少促炎细胞因子并提高生存率

Has acceptable tolerability in initial studies in humanized mice

在人源化小鼠的初步研究中具有可接受的耐受性

'Our preclinical data underscore the potential of our KIR x ICOS CD8 Treg Modulator as a selective therapeutic approach for highly inflammatory autoimmune diseases, including Crohn's disease and ulcerative colitis. Findings show that the Modulator is selective toward CD8 Treg, efficacious in models of disease, and has an encouraging safety profile,' said Dr.

“我们的临床前数据强调了我们的KIR x ICOS CD8 Treg调节剂作为高度炎症性自身免疫性疾病（包括克罗恩病和溃疡性结肠炎）的选择性治疗方法的潜力。研究结果表明，该调节剂对CD8 Treg具有选择性，在疾病模型中有效，并且具有令人鼓舞的安全性。

Kristine Swiderek, Chief Scientific Officer at Mozart Therapeutics. 'The data support further advancement of this promising molecule.'.

莫扎特治疗公司（MozartTherapeutics）首席科学官克里斯蒂娜·斯威德里克（KristineSwiderek）数据支持这种有前途的分子的进一步发展。”。

Presentation Details:

演示详细信息：

Abstract:

摘要：

#4471, Poster Board #883

#4471，海报板#883

Session:

会议：

May 6, 2024, at 11:30 a.m. Central Daylight Time

2024年5月6日，中央夏令时上午11:30

Poster Title:

海报标题：

Pre-clinical Pharmacology and Tolerability Characterization of a Novel KIR x ICOS Targeting Bispecific CD8 Treg Modulator'

靶向双特异性CD8 Treg调节剂的新型KIR x ICOS的临床前药理学和耐受性表征

The poster can be accessed from the Mozart Therapeutics website following the May 6 presentation.

在5月6日的演示之后，可以从Mozart Therapeutics网站访问海报。

About KIR x ICOS Modulator

关于KIR x ICOS调制器

Inhibitory killer immunoglobulin-like receptors (KIR) are autoimmune checkpoints expressed on CD8 regulatory T cells, limiting their function of killing pathogenic CD4 T cells.

抑制性杀伤免疫球蛋白样受体（KIR）是在CD8调节性T细胞上表达的自身免疫检查点，限制了它们杀死致病性CD4 T细胞的功能。

The inducible T cell costimulator (ICOS) is upregulated on activated CD8 Treg and critical to CD8 Treg function.

诱导型T细胞共刺激分子（ICOS）在活化的CD8 Treg上上调，并且对CD8 Treg功能至关重要。

KIR x ICOS is a bispecific antibody targeting CD8 Treg. The molecule aims to restore CD8 Treg function through inhibition of KIR, while promoting ICOS-mediated CD8 Treg activation, in chronic and highly inflammatory autoimmune disease.

KIR x ICOS是靶向CD8 Treg的双特异性抗体。该分子旨在通过抑制KIR来恢复CD8 Treg功能，同时在慢性和高度炎症性自身免疫性疾病中促进ICOS介导的CD8 Treg活化。

About Mozart Therapeutics

关于莫扎特疗法

Mozart Therapeutics is focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, utilizing a novel approach to restoring immune system homeostasis by targeting the CD8 Treg network. The company is headquartered in Seattle, WA. For more information, visit www.mozart-tx.com and follow the company on LinkedIn @Mozart-tx..

Mozart Therapeutics专注于开发针对自身免疫和炎症性疾病的一流疾病缓解疗法，利用一种新方法通过靶向CD8 Treg网络来恢复免疫系统稳态。该公司总部位于华盛顿州西雅图。有关更多信息，请访问www.mozart-tx.com，并通过LinkedIn@mozart-tx关注该公司。。

Media Contact:Julie RathbunRathbun Communicationsjulie@rathbuncomm.com206-769-9219

媒体联系人：朱莉·拉斯本拉斯本Communicationsjulie@rathbuncomm.com206-769-9219

SOURCE Mozart Therapeutics

来源：莫扎特疗法